It can be used to evaluate the risk of patients progressing to CRPC and the degree of benefit from ADT through its combination with PSA level in clinical practice, which is helpful for clinicians to select individualized treatment methods for prostate cancer patients. This evidence concerns the gene KLK3 and prostate cancer.